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Abstract
Activating mutations in the Kras gene are commonly found in some but not all epithelial cancers. In order to understand the
susceptibility of different epithelial tissues to Kras-induced tumorigenesis, we introduced one of the most common Kras
mutations, Kras
G12D, broadly in epithelial tissues. We used a mouse model in which the G12D mutation is placed in the
endogenous Kras locus controlled by inducible, Cre-mediated recombination in tissues expressing cytokeratin 19 including
the oral cavity, GI tract, lungs, and ducts of the liver, kidney, and the pancreas. Introduction of the Kras
G12D mutation in adult
mouse tissues led to neoplastic changes in some but not all of these tissues. Notably, many hyperplasias, metaplasias and
adenomas were observed in the oral cavity, stomach, colon and lungs, suggesting that exposure to products of the outside
environment promotes Kras
G12D-initiated tumorigenesis. However, environmental exposure did not consistently correlate
with tumor formation, such as in the small intestine, suggesting that there are also intrinsic differences in susceptibility to
Kras activation. The pancreas developed small numbers of mucinous metaplasias with characteristics of early stage
pancreatic intraepithelial neoplasms (PanINs), supporting the hypothesis that pancreatic ducts have the potential to give
rise pancreatic cancer.
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Introduction
Cancer is thought to arise from a series of genetic and epigenetic
changes that confer oncogenic properties on a cell and its
descendents (reviewed in [1]). A number of oncogenes can
contribute to cancer initiation or progression but none have been
found to be sufficient for tumor formation. Rather, other genes
must be mutated, silenced or overexpressed, within the cell or its
environment, for a tumor to form. Kras is a proto-oncogene that
normally relays signals from a variety of transmembrane receptors
to intracellular effectors that regulate processes such as prolifer-
ation, survival, and migration. While its activity is tightly
regulated, somatic mutations occur that render its activity
constitutive and thereby oncogenic (reviewed in [2]). Activating
mutations in Kras are found in histologically normal tissues as well
as in tumors [3] indicating that while these mutations naturally
accumulate over the lifetime of an individual, they only rarely lead
to tumor formation.
Underscoring the ability of Kras mutations to contribute to
tumor formation, they are common in many epithelial tumors
including cancers of the pancreas, colon, and lung but are rare in
cancers of the oral cavity and stomach [4]. The underlying
mechanism for this tissue-specificity remains unexplored. It is
possible that different cell types have different susceptibilities to the
neoplastic effects of mutant Kras or that different tissues are more
or less subject to Kras mutation. Kras appears to play different
roles in different cancers, suggesting there are tissue-specific
susceptibilities to Kras mutation. For example, in the pancreas,
Kras mutation is an early step in tumor initiation [5]. However, in
the colon, tumor initiation is thought to arise largely through
aberrant activation of the Wnt signaling pathway with Kras
mutation playing a later role in tumor progression [6].
One of the strongest correlations between cancer and Kras
mutation occurs in pancreatic ductal adenocarcinoma (PDAC)
which has Kras mutations in approx. 95% of cases [7]. Mouse
models have shown that introducing mutant Kras throughout the
pancreas beginning in embryogenesis results in many pancreatic
intraepithelial neoplasms (PanINs) [8] that are thought to be the
precursors of PDAC [9]. When combined with loss of tumor
suppressor genes, these PanIN lesions progress to invasive and
metastatic PDAC [10,11,12]. The genetic tools used to activate
Kras during pancreatic development target mutant Kras to all cells
of the pancreas, including both acinar and duct cells of the
exocrine pancreas, making ontogeny of tumors impossible to
determine. Because PDAC in humans has morphologic and
molecular markers of duct-like cells, it was long held that
neoplastic transformation of normal pancreatic ducts gives rise
to PDAC [13]. However, we and others have recently shown that
pancreatic acinar cells are capable of changing their cellular
identity, or transdifferentiating, into duct-like cells in response to
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origin of PDAC. Understanding how PDAC arises is important for
identifying appropriate biomarkers of cancer development as well
as identifying targets that might be relevant in the treatment of
human disease.
We have recently developed a genetic tool that allows us to
investigate the susceptibility of different epithelial tissues to
Kras
G12D-initiated tumorigenesis in adult mice. Because epithelial
tumors of some tissues are frequently associated with Kras
mutation and those of other tissues are rarely associated, we
tested the hypothesis that some tissues are refractory to the effects
of Kras mutation, as opposed to being susceptible to its effects but
rarely undergoing its mutation, by introducing the mutation into
multiple tissues. We found that Kras
G12D could induce neoplastic
changes in multiple, although not all, assayed tissues. Susceptible
tissues included those which in humans rarely have Kras
mutations as well as those that frequently do. There was some
correlation of susceptibility with exposure to the outside
environment, suggesting that environmental factors may play a
major role in promotion of Kras
G12D-initiated tumors. However,
this correlation was not uniform indicating that there are also
intrinsic differences in how cells respond to Kras activation.
Additionally, we demonstrate that pancreatic ducts are capable of
giving rise to mucinous metaplasias with characteristic of early
PanIN lesions.
Results
CK19
CreERT produces recombination in multiple epithelial
tissues
Kras
G12D mutation was targeted to multiple epithelial tissues via
the CK19
CreERT [17] and LSL-Kras
G12D [18] genetically
engineered insertional alleles. The LSL-Kras
G12D allele cannot
be expressed until Cre recombinase removes a transcriptional stop
cassette, positioning the mutated coding sequence in line with the
endogenous Kras promoter. CK19
CreERT encodes the Cre
recombinase fused to a region of the estrogen receptor that has
been mutated to bind tamoxifen. This ERT domain prevents Cre
from entering the nucleus and inducing recombination until it
binds tamoxifen. For these studies, tamoxifen was injected into
adult mice, abrogating embryonic effects. The CreERT coding
region was inserted in exon 1 of the Cytokeratin 19 gene, a
structural protein found in many epithelial tissues. We have shown
previously that CK19
CreERT can activate a loxP-flanked reporter
in cells throughout the gastrointestinal tract and in ducts of the
pancreas, liver, and kidney [17]. Thus, CK19
CreERT can activate
Kras
G12D in cells of all these tissues.
In the course of these studies, we also found that CK19
CreERT
was active in lung and oral cavity. In the lung, CK19 protein is
widely expressed in all epithelium [19,20]. However, we found
that CK19
CreERT recombined the R26R
EYFP reporter largely in
bronchi and bronchioles (28+/210% of cells labeled) and rarely in
alveoli (0.22+/20.08% labeled) (n=3 mice; Figure 1A, B and data
not shown). CK19 protein is a minor component of oral
epithelium [21]. Accordingly, when CK19
CreERT was cross to
the R26R
EYFP reporter [22], we found a low frequency of labeling
in squamous epithelium of both the lingual and buccal surfaces
(Figure 1C, D). Because only basal cells are retained for extended
lengths of time, we determined the percent of basal cells in lingual
and buccal surfaces that were labeled by CK19
CreERT and found
that 0.82+/20.42% (n=3) were positive for the EYFP reporter.
Other tissues including the stomach, small intestine, colon,
pancreas and liver were labeled as previously described [17].
Fifteen CK19
CreERT; LSL-Kras
G12D mice and littermate
controls were given tamoxifen at 6–8 weeks of age and then
followed for up to 6 months. Mice were monitored weekly for signs
Figure 1. CK19
CreERT recombined an EYFP reporter in lung and oral cavity. Bronchus (A), bronchiole (B), lingual epithelium (C), and buccal
epithelium (D) from CK19
CreERT; R26R
EYFP mice immunolabeled for EYFP (brown). Arrows in C and D, labeled cells in basal layer of epithelia. Size bars,
50 mm.
doi:10.1371/journal.pone.0016786.g001
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of 15 CK19
CreERT; LSL-Kras
G12D mice were euthanized due to
loss of at least 20% body weight (Figure 2). No weight loss or other
distress was observed in any mouse that had only one of the
CK19
CreERT or the LSL-Kras
G12D alleles.
Kras
G12D mutation induced oral papillomas
Loss of weight was correlated with the presence of large masses
in the oral cavity. Histological analyses revealed the presence of
squamous papillomas of the posterior tongue and/or buccal
surface of all mice that lost .20% body weight (Figure 3A, B).
Papillomas of the posterior tongue were found in 100% percent of
CK19
CreERT; LSL-Kras
G12D mice while these lesions less
commonly involved the buccal surface, occurring in seven of
thirteen bigenic mice aged 4–6 months post-tamoxifen treatment.
Interestingly, lingual papillomas were limited to the back of the
tongue even though CK19
CreERT labeled cells randomly across the
anterior-posterior axis of the tongue. The proliferative zone in all
papillomas was maintained in the basal cell layer (Figure 3C) and
no dysplasia was observed. No oral cavity phenotype resulted from
tamoxifen injection or from heterozygosity of the CK19 or Kras
alleles, as all mice with single genetically engineered alleles injected
with tamoxifen had normal phenotype in all tissues examined.
Kras
G12D mutation induced lung adenoma formation
At no time during the study was any difficulty in breathing
observed in mice even though we found CK19
CreERT was active in
lung bronchi and bronchioles. However, upon dissection, lungs of
CK19
CreERT; LSL-Kras
G12D mice were enlarged with an average
wet weight of 0.676+/20.053g compared to 0.175+/20.014 g for
control lungs at 6 months post-tamoxifen (p,0.001; n=5
CK19
CreERT; LSL-Kras
G12D, 9 single transgene controls). All
CK19
CreERT; LSL-Kras
G12D mice at 6 months post-tamoxifen had
visible tumors up to 3 mm in diameter. Upon histological analysis,
all CK19
CreERT; LSL-Kras
G12D mice had multiple benign lung
tumors consisting primarily of papillary adenomas that became
densely packed in the larger lesions (Figure 4A, B) [23] while all
single gene controls were histologically normal.
Kras
G12D mutation induced gastric metaplasia
All CK19
CreERT; LSL-Kras
G12D mice exhibited metaplasia in
the fundus of the stomach by 4–6 months after tamoxifen
administration while single gene controls exposed to tamoxifen
were morphologically and histologically normal. The number of
affected glands in CK19
CreERT; LSL-Kras
G12D mice ranged from
10–50% along the lesser curvature of the stomach with a
decreasing frequency farther from the lesser curvature. Affected
glands were characterized by foveolar hyperplasia as seen by the
extended zone of PAS staining for mucin (Figure 5A), reduced
presence of parietal cells (data not shown) and a proliferative zone
deeper in the affected glands than in unaffected glands (Figure 5B).
TFF2, a marker of mucous neck cells, also showed staining deeper
in the glands, indicating that the mucous neck region was located
near the base rather than the normal location approx. two-thirds
the distance from the base (Figure 5C). Staining with alcian blue
yielded a light diffuse staining rather than the dark, punctate
pattern seen in intestinal metaplasia (data not shown).
Kras
G12D mutation led to pancreatic ductal lesions
Within the pancreas, CK19
CreERT recombines loxP-flanked
alleles in ductal cells with less than 1% recombination in islet and
acinar cells [17]. Therefore, this allele allowed us to test the
hypothesis that ducts could be the origin of pancreatic ductal
adenocarcinoma (PDAC) [13]. At dissection, the pancreas
appeared grossly normal in CK19
CreERT; LSL-Kras
G12D mice.
To detect any morphological changes, we examined sections every
200 mm through each pancreas. All five bigenic mice examined at
6 months of age exhibited at least one mucinous ductal metaplasia
with features of early mouse pancreatic intraepithelial neoplasm,
or mPanIN1A, thought to be the earliest stage of neoplasm leading
to PDAC (Figure 6A) while control littermates were morpholog-
ically and histologically normal. Of the 6 bigenic mice examined at
4.5 months post-tamoxifen treatment, two had these mucinous
ductal lesions (data not shown). Six of all lesions were found in the
tail, three in the body, and two in the head of the pancreas.
Examination of serial sections showed that all lesions were
continuous with normal pancreatic ducts (Figure 6B) suggesting
that they did indeed arise via activation of Kras in pancreatic
ducts. At the interface between morphologically normal and
abnormal cells, staining with alcian blue demonstrated that
morphologically normal cells near the transition site expressed
low levels of mucin whereas alcian blue staining was not observed
in any normal ducts not associated with ductal lesions. Thus, a
progression could be observed from cuboidal, non-mucinous to
cuboidal, mucinous to columnar, mucinous cells within one duct.
We also determined whether pancreatic lesions in CK19
CreERT;
LSL-Kras
G12D mice expressed claudin-18, which is highly
expressed in PanINs and PDAC but not in normal ducts or
reactive ducts that are commonly seen in chronic pancreatitis [24].
As shown in Figure 6C, all mucinous lesions found expressed
claudin-18. No other cells in the pancreas including normal ducts
had detectable claudin-18 (data not shown). The ducts that were
contiguous with mucinous lesions were all the larger interlobular
or intralobular ducts that express the CK19
CreERT allele. Because
CK19
CreERT does not produce Cre recombinase activity in the
smaller intercalated ducts, we could not determine whether all
ducts of the pancreas could give rise to PanIN-like lesions but can
clearly conclude that larger ducts are capable of giving rise to
mucinous neoplasms characteristic of early PanIN lesions.
Figure 2. Morbidity analysis: epithelial expression of Kras
G12D
led to weight loss. Mice were monitored weekly for weight and other
indications of overall health. Number maintaining at least 80% of
highest body weight is plotted as a function of time for CK19
CreERT; LSL-
Kras
G12D (solid line) and for littermates also injected with tamoxifen
(dashed line). An additional 3 control mice were also injected with
tamoxifen but were only followed for 3–5 months as controls for earlier
timepoints and did not lose weight during that time (data not shown).
doi:10.1371/journal.pone.0016786.g002
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G12D mutation induced metaplasia in the colon
In many patches of the ascending colon, villus-like structures
were observed surrounded by areas of normal crypt structure in
CK19
CreERT; LSL-Kras
G12D mice (Figure 7A). Similar but less
distinct villus-like projections were also seen in smaller numbers
(1–3 per section) in more distal parts of the colon (data not shown).
These villus-like projections did not have apparent Paneth cells
and so may not have been a homeotic transformation to small
intestine. The tops of projections were approximately the same
height as surrounding crypts and they were not associated with
increased proliferation (Figure 7B). These structures are morpho-
logically similar to those recently reported as murine serrated
hyperplasia capable of giving rise to serrated carcinoma in a
mouse model [25]. Single gene control mice had no intestinal
phenotype.
Some tissues appeared unaffected by Kras
G12D activation
We have reported previously that the CK19
CreERT allele is
active in hepatic ducts, renal papillary ducts and throughout the
small intestine. However, upon examination of random sections
through each of these tissues in each CK19
CreERT; LSL-Kras
G12D
mouse at 4–6 months post-tamoxifen, we failed to find any
morphological abnormalities in liver, kidney or small intestine.
Because CK19
CreERT has a high rate of recombination in the
small intestine but no morphological phenotype, we also
immunolabeled this tissue for markers of proliferation, phospho-
histone H3 and Ki67. All intestinal crypts had a normal number of
proliferating cells (data not shown). Thus, Kras
G12D mutation
alone is not sufficient to alter homeostasis in this tissue.
One reason for tissue-specific differences in Kras
G12D
susceptibility could be a difference in the extent of recombina-
tion of the LSL-Kras
G12D allele. While we had shown that
CreERT produced from the CK19 allele could recombine the
R26R
EYFP allele in all these tissues, different alleles may have
different rates of recombination due to loxP flanking sequences
or higher level chromatin structure. Therefore, we performed
PCR analysis of DNA extracted from each of the tissues that
had little or no phenotype in CK19
CreERT;L S L - K r a s
G12D mice,
as well as from stomach which had a strong phenotype, and
from tail DNA as a negative control. As expected, the Kras
G12D
allele was recombined in stomach but was also recombined to
s o m ee x t e n ti ns m a l li n t e s t i n e ,c o l o n ,l i v e r ,p a n c r e a s ,a n d
kidney while no recombination was detected in tail DNA
(Figure 8A). The amount of recombination was barely
detectable in liver and kidney perhaps due to the small number
of duct cells in each of those tissues that had shown
recombination of the R26R
EYFP allele [17]. Because the
intestine had a seemingly high amount of recombination of
the Kras
G12D allele but no apparent phenotype, we compared
the amount of recombined allele present in the small intestine to
that in oral papillomas, where the majority of epithelium should
have recombined the Kras
G12D allele (although there was some
submucosa present in which CK19
CreERT is not active). As
expected, the amount of recombination (upper bands in
Figure 8B) was much higher in isolated papillomas than in
total oral tissue. The amount of recombination in intestine was
higher than in total oral tissue but less than that seen in the
papillomas. This is consistent with the observed activity of
CK19
CreERT being high in intestine but not recombining in
every cell. In conclusion, CK19
CreERT was able to recombine
the Kras
G12D allele in multiple epithelial tissues even when no
resulting phenotype was observed.
Figure 3. Kras
G12D led to squamous papillomas in the oral cavity. A.H&E staining of papillomas on back of tongue. B. H&E staining of buccal
papillomas. C. Immunolabeling for phosphohistone H3 (brown), an M phase marker, revealed that the proliferative zone in papillomas remained in
the basal layer. Size bars, 50 mm.
doi:10.1371/journal.pone.0016786.g003
Figure 4. Kras
G12D mutation led to adenoma formation in
lungs. A, B. PAS and hematoxylin staining of lung adenomas typical of
CK19
CreERT; LSL-Kras
G12D mice. Size bars, 50 mm.
doi:10.1371/journal.pone.0016786.g004
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Environmental impact on Kras
G12D-initiated
tumorigenesis
While the CK19
CreERT mouse can activate Kras
G12D in many
epithelial tissues of the mouse, this activation only induced
widespread neoplasia in three tissues, the oral mucosa, stomach,
and lung. Of the tissues targeted by CK19
CreERT, these tissues are
among the most exposed to the outside environment. This suggests
that environment-induced damage or mutation may cooperate
with Kras mutation to promote tumor formation. However,
anterior tongue and the small intestine did not develop detectable
neoplastic changes in response to Kras
G12D mutation. Therefore,
environmental exposure cannot be the only factor in susceptibility.
Rather, cells must also have intrinsic differences in their response
to the Kras
G12D mutation.
Some tissue susceptibility may arise from differences in
Kras mutation rate
In two cases, Kras
G12D initiated neoplastic changes in tissues
that rarely have Kras mutations in corresponding human cancers.
In both the oral cavity and stomach, frequent and profound
hyperplasia resulted from Kras
G12D expression, yet cancers of
these tissues in humans rarely carry Kras mutations. No
information exists on the actual rate of Kras mutation in normal
human tissues and we cannot rule out species-specific differences.
However, our results combined with other studies discussed below,
suggest that some epithelial tumors or hyperplasias do not carry
Figure 5. Kras
G12D mutation led to foveolar hyperplasia in the gastric fundus. A. PAS (pink) showed extensive mucin production deep into
affected glands while surrounding normal glands only had staining at the tops of glands. B. Immunolabeling for phosphohistone H3 as an M phase
marker. The proliferative zone in affected glands was shifted toward the base of the glands. C. Immunolabeling for TFF2 (brown) showed positive
cells near base of affected fundic glands while normal glands had expression in the normal mucous neck region. Arrows, staining in affected glands;
arrowheads, staining in normal glands. Size bars, 50 mm.
doi:10.1371/journal.pone.0016786.g005
Figure 6. Kras
G12D mutation led to mucinous metaplasia in pancreatic ducts. H&E staining of a typical lesion in mouse pancreas (A) and its
connection to normal ductal epithelium in a nearby serial section (B) with alcian blue staining to denote mucin-producing cells. Arrowhead, junction
between nonmucinous and mucinous cells; arrows, junction between cuboidal and columnar cells. (C) Mucinous lesions were all strongly positive for
claudin-18 (brown) with highest concentrations along lateral cell borders. Size bars, 50 mm.
doi:10.1371/journal.pone.0016786.g006
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mechanisms that upregulate Kras activity. This may reflect a
lower rate of occurrence of Kras mutation in these tissues or a
higher rate of other mutations/events that affect Kras activity.
One of these tissues is the oral mucosa. Caulin et al. [26] also
showed that Kras
G12D can induce squamous papillomas in oral
mucosa, using an inducible Cre transgene regulated by the CK14
promoter to activate the LSL-Kras
G12D allele. Although activating
mutations in Kras are found in only 4–7% of squamous cell
carcinoma of the head and neck (HNSCC) in humans [27,28],
Kras protein is often elevated in this cancer suggesting that its
activity plays a critical role in tumor initiation or progression.
Supporting this role, a low level of expression of microRNA let-7d
and a polymorphism in a let-7 microRNA binding site in the Kras
39UTR are associated with poor survival from HNSCC [29,30]
and let-7 has been shown to regulate Kras expression [31].
In stomach cancer, there have been reports that Kras may also
be regulated by microRNAs and/or by gene amplification [32,33].
We showed that Kras
G12D can induce frequent metaplasia in
gastric fundus. These metaplastic glands displayed characteristics
of foveolar hyperplasia with an extended zone of PAS-positive
surface mucous cells, oxyntric atrophy, and basal expression of
TFF2. Foveolar hyperplasia is associated with conditions such as
Menetrier’s disease rather than gastric cancer [34]. It will be
interesting in future studies to determine whether these Kras-
initiated hyperplasias in stomach mucosa can progress to invasive
or metastatic disease.
Cell of origin in lung and pancreatic cancers
In lungs, the CK19
CreERT allele produced recombination
mostly in bronchi and bronchioles leading to the papillary
adenomas observed in the CK19
CreERT; LSL-Kras
G12D mice.
These tumors were quite different than those observed when the
LSL-Kras
G12D allele was activated by nasal installation of
adenovirus encoding Cre recombinase [18,35]. The difference
likely reflects different cells of origin for tumor formation. Since we
determined that CK19
CreERT is active primarily in bronchi and
bronchioles, it is likely that inhaled viral delivery targets mainly
other cell types such as alveolar cells.
The cell of origin of pancreatic ductal adenocarcinoma has
been widely debated. While these lesions in humans consist
Figure 7. Kras
G12D mutation was associated with patches of
villus-like structures in the ascending colon. A. H&E staining
shows villus-like architecture in an area of the ascending colon. Normal
colonic crypt structure resumes on upper right side of each panel
(arrowhead). B. Immunolabeling for Ki67 (brown) indicates that the
proliferative zones associated with villus-like structures are similar in cell
number to normal colonic crypts. Size bars, 50 mm.
doi:10.1371/journal.pone.0016786.g007
Figure 8. Cre-mediated recombination of the LSL-Kras
G12D
allele in different tissues. A. DNA was extracted from the indicated
tissues of three different mice and subjected to 35 cycles of PCR that
would detect both the wildtype Kras allele (271 bp) and the
recombined LSL-Kras
G12D allele (310 bp) but not the unrecombined
LSL-Kras
G12D allele. Tissues examined: 1) tail, 2) small intestine, 3) liver, 4)
pancreas, 5) kidney, 6) stomach, and 7) colon. Strong recombined bands
were detected for small intestine, pancreas and colon and weaker
bands for stomach, kidney and liver, while recombination was never
detected in tail DNA. B. The amount of recombination of an unaffected
tissue, the small intestine, was compared to the amount in an oral
papilloma in which all or nearly all of the epithelium should have a
recombined Kras allele. For three different mice, DNA was prepared
from total oral tissue (lanes 1–3), isolated papilloma tissue (lanes 4–6)
and total small intestine tissue (lanes 7–9) and subjected to 30 cycles of
PCR. Little recombination can be detected in total oral tissue while the
recombination is abundant in the isolated papilloma (upper band in
each lane). The amount of recombination in the small intestine was
intermediate between these two populations.
doi:10.1371/journal.pone.0016786.g008
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amazing plasticity in the adult pancreas, showing that acinar cells
readily give rise to ductal epithelium, notably to mucinous,
hyperplastic epithelium in the case of transgenic overexpression
of the growth factor TGFa [14]. Furthermore, studies have
shown that using an acinar-specific CreERT allele to activate
Kras
G12D results in a low frequency of mPanIN1A lesions by 2
months post-tamoxifen treatment and progression to later stage
PanINs as mice age [36,37]. Similarly, expression of Kras
G12V in
acinar cells also led to mPanIN and PDAC but only in
conjunction with chemically induced pancreatitis [38]. Thus, at
least in the mouse, acinar cells are capable of giving rise to
PanIN-like lesions and PDAC.
Until now, the tools to direct Kras
G12D mutation to pancreatic
ducts have been lacking and testing the ductal compartment as the
cell of origin for PanIN or PDAC was not possible. We now show,
using the CK19
CreERT allele to activate the Kras
G12D allele, that
pancreatic ducts can give rise to lesions with the morphological
and molecular characteristics of early PanINs. While these cells
have the characteristics of early PanIN lesions, we cannot
conclude at this point that they are true ‘‘PanINs,’’ because they
did not give rise to PDAC in the course of our analysis. Future
studies will determine the ability of these lesions to progress to
invasive or metastatic disease when combined with loss of tumor
suppressor genes or with induction of pancreatitis.
Because CK19
CreERT is expressed in a small percentage of
acinar cells [17], it is possible that those few cells gave rise to the
lesions reported here. This is unlikely for two reasons. One, our
model had recombination in ,1% of acinar cells while the acinar-
specific Elastase-CreERT: LSL-Kras
G12D model had 50% of
acinar cells recombined and yet had a similar number of PanIN
lesions arise as we did in our study [36]. Since CK19
CreERT labels
,1% of acinar cells [17], we would expect to see a much lower
frequency (,1/50
th the number) of lesions than those seen from
elastase-driven activation of Kras
G12D if acinar cells were the cell
of origin in our study. Two, the PanIN-like lesions resulting from
CK19
CreERT activation were continuous with normal ductal
epithelium. Comparing our results and those described above,
we conclude that both duct and acinar cells are capable of giving
rise to mucinous lesions with PanIN-like characteristics and
therefore potentially to PDAC.
Some tissues in the adult are refractory to Kras
G12D-
initiated tumorigenesis
We did not observe hyperplasia in the intestinal tract
although CK19
CreERT is widely expressed in this mucosa [17]
and a substantial amount of recombination of the Kras
G12D
allele was seen (Figure 8). Jacks and colleagues [18,39] reported
that activation of the LSL-Kras
G12D allele via the FABP-Cre
transgene resulted in extensive hyperplasia along the crypt-villus
axis throughout the intestine. Rather, we found only induction
of altered crypt architecture in the colon and no phenotype in
the small intestine. One difference between that study and ours
is the timing of Kras
G12D activation. FABP-Cre is active
embryonically [40] whereas we did not activate CK19
CreERT
until 6–8 weeks of age. In the pancreas, embryonic activation of
the Kras
G12D allele resulted in widespread early neoplasms with
occasional progression to more advanced lesions [8]. However,
activation in adult acinar cells [36,37] or adult ducts (reported
here) gave only rare lesions unless further injury was induced
[38]. A similar phenomenon may occur in the intestine, where
Kras
G12D in the embryonic epithelium induces changes that
result in a higher susceptibility to tumorigenesis. Perhaps adult
tissues are intrinsically more refractory to the effects of activated
Kras or else the embryonic environment (e.g., the abundant
mesenchyme that often regulates epithelial development)
promotes oncogenic events that do not necessarily become
apparent until after birth.
The studies presented here clearly show that different tissues
have different susceptibilities to Kras
G12D-initiated tumorigenesis.
This differential susceptibility is most evident in the small intestine
which had a high rate of recombination of the LSL-Kras
G12D
allele with no apparent resulting phenotype. This could be due to
multiple mechanisms. It could be that Kras regulates different
signaling pathways in different cells and that some pathways are
more oncogenic than others. Supporting differences in Kras
function, high level of Kras
G12D may induce tumorigenesis in
some cells but will induce senescence in other cells [41,42].
Alternatively, susceptibility may depend upon the level of Kras
expression. While Kras expression has been found in all tissues
examined [43,44,45], its relative expression level among different
tissues varies [45]. Those experiments were limited in that they did
not look at expression in each cell type, but clearly indicated that
Kras expression, while ubiquitous, has some tissue-specific
regulation. For example, liver has a lower level of Kras expression
than many other tissues while gut has among the highest level of
Kras expression. Low expression of Kras may explain the inability
of Kras
G12D to induce liver tumors but does not explain the
inability of Kras
G12D to induce intestinal tumors. The activity of
oncogenes is frequently abrogated by the expression of tumor
suppressor genes. Tissues may vary in which tumor suppressors
are expressed, how many are expressed, and how readily they are
silenced. It is likely that future studies will uncover multiple
mechanisms that vary from tissue to tissue, allowing some cells to
maintain homeostasis in the face of Kras activation while others
become transformed.
Materials and Methods
Mice
All experiments were performed with approval from the
Vanderbilt Institutional Animal Care and Use Committee, Animal
Welfare Assurance number A3227-01, protocol numbers M/06/
078 and M/09/394. CK19
CreERT [17], LSL-Kras
G12D [18] and
R26R
EYFP [22] mice were previously published and were bred for
at least 8 generations into the C57BL6/J background. At 6–8
weeks of age, mice were administered tamoxifen or corn oil vehicle
3 times over the course of 5 days at a dosage of 1 mg in 50 ml each
time. Mice were weighed weekly and euthanized if weight
decreased by more than 20%. Fifteen bigenic CK19
CreERT;
LSL-Kras
G12D mice were analyzed as well as 15 littermate controls
that were wildtype or had either the CK19
CreERT or the LSL-
Kras
G12D allele but not both.
Histology
Tissues were fixed in 4% paraformaldehyde for 4–5 h at 4uC,
except tissues for EYFP detection which were fixed overnight,
washed in 70% ethanol and embedded in paraffin after
dehydration through a series of increasing ethanol concentrations
and Histoclear (National Diagnostics, Atlanta, GA). Paraffin
sections were cut at a depth of 5 mm. Antibodies used were rabbit
anti-GFP (Novus Biological, Littleton, CO), mouse anti-TFF2 (a
kind gift of Nick Wright), rabbit anti-phosphohistone H3
(Millipore, Telecuma, CA), rabbit anti-claudin-18 (Zymed/
Invitrogen, Carlsbad, CA) and mouse anti-Ki67 (Novocastra,
Newcastle upon Tyne, UK). Mucin was detected by staining with
periodic acid-Schiff reagent (Sigma, St. Louis, MO) as per
manufacturer’s instructions or with Alcian blue, pH 2.5 (Sigma).
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Tissue was scraped from slides and digested with proteinase K
in DirectPCR lysis buffer (Viagen Biotech Inc, Los Angeles, CA).
Lysates were heat-inactivated, extracted with phenol and chloro-
form, precipitated with isopropanol, resuspended and 100 ng used
in polymerase chain reaction (PCR) as described [26] with primer
sequences KRasLox-F2: 59CAGTGCAGTTTTGACACCAGC-
T39, and KRasLox-R1: 59GCATAGTACGCTATACCCTGTG-
GA39 and 30–35 cycles of amplification as indicated.
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